Notably, it was anticipated that the keyword trends concerning “cancer immunotherapy,” “bispecific antibody,” “monoclonal antibody,” “multiple myeloma” and “antibody-dependent enhancement” would persist into 2025, underscoring their enduring relevance as key subjects within the field of FcγR. This evidence concerns the gene FCGR2A and AL amyloidosis.